Evidence map›Paper›PMID 29804205›Full record

ArticleInfection2018

HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.

Viola Guardigni, Valeria Cento, Stefano Ianniruberto, Lorenzo Badia, Marianna Aragri, Matteo Conti, Carlo Federico Perno, Pierluigi Viale, Francesca Ceccherini-Silberstein, Gabriella Verucchi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Viola GuardigniInfectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. v.guardigni@gmail.com.ORCID http://orcid.org/0000-0002-2769-7325
Valeria CentoUniversity of Milan, Milan, Italy.
Stefano IannirubertoInfectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Lorenzo BadiaInfectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Marianna AragriDepartment of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Matteo ContiMetropolitan Laboratory, Maggiore Hospital, Bologna, Italy.
Carlo Federico PernoDepartment of Oncology and Heamato-Oncology, University of Milan, Milan, Italy.
Pierluigi VialeInfectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Gabriella VerucchiInfectious Diseases Unit, Department of Medical and Surgical Science, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct-acting antivirals (DAAs) for the treatment of HCV have dramatically increased the rate of sustained virological response: patients not achieving sustained virological response represent a challenge and rates of late recurrent viremia are very low. We describe here the first case of a very late HCV relapse, following an atypical kinetics (characterized by a spontaneous but transient HCV clearance after an early virological relapse), in a HIV co-infected patient treated with DAAs. Optimal adherence to the therapy was well documented and a phylogenetic analysis ruled out a possible reinfection from a different HCV strain. In conclusion, our case underlines the importance of a long follow-up (> 48 weeks) after DAAs therapies in HCV-HIV co-infected patients who might benefit the most from a very rigorous virological surveillance.

Indexed as

CoinfectionViral LoadAntiviral AgentsGenotypeHepacivirusHepatitis CHIV InfectionsHumansMaleMiddle AgedPhylogenyRecurrenceRNA, ViralTreatment OutcomeAntiviral AgentsRNA, ViralAntiviral therapyHepatitisHIV infectionIFN-free regimensMaravirocRecurrence

Identifiers

PMID29804205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.